Compare Ginkgo Bioworks Holdings Inc (DNA) vs Fubotv Inc (FUBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Fubotv Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.95 (market cap $763.64M), while Fubotv Inc trades at $8.92 (market cap $1.02B). The key difference: Fubotv Inc is the larger of the two by market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Fubotv Inc for 35 Days on average.
| DNA | FUBO | |
|---|---|---|
Market Cap | $763.64M | $1.02B |
Volume | 3,204,177 | 978,631 |
Sector | Health | Media |
52-Week High | $15.83 | $48.96 |
52-Week Low | $5.48 | $8.09 |
Typical Hold Time | 7 Days | 35 Days |
Enterprise Value | $865.59M | $1.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.
While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.
FUBO trades at $8.84, down 4.43% today, with bearish technical signals from moving averages but neutral oscillators. The company shows improving fundamentals with revenue growth to $1.62B in 2024 and a projected net profit of $123M in 2025. Recent developments include new sports streaming agreements with NHL and TBL Team Boxing League, while analyst consensus remains mixed with 47% buy ratings and a $63.38 price target.
FUBO presents a turnaround story with improving profitability metrics and strategic content partnerships driving growth potential. However, risks include persistent negative cash flow, high debt levels, and intense streaming competition. The stock's current valuation appears attractive with P/E of 2.43 and P/S of 0.19, but execution risks remain significant for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →
